Skip to Main Content

Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty

  • Study HIC#:2000025198
  • Last Updated:07/15/2021

Brief Summary:

Preoperative quadratus lumborum block (QLB)/lateral femoral cutaneous nerve block (LFCNB) with ropivacaine and glucocorticoids provide more effective analgesia than periarticular injection (PAI) with the same mixture in total hip arthroplasty (THA).

  • Age18 years and older
  • GenderBoth
  • Start Date11/10/2019
  • End Date03/30/2021

Trial Purpose and Description

To support our hypothesis that preoperative quadratus lumborum block (QLB)/lateral femoral cutaneous nerve block (LFCNB) provides more effective analgesia than periarticular injection (PAI) in total hip arthroplasty (THA), we will look at the following outcomes:

Primary outcome: Daily opioid consumption
Secondary outcomes:
[1]. Pain intensity and physical functioning while in the hospital: using pain inventory modified from Brief Pain Inventory 23
[2]. Boston mobility scores (from physical therapy note);
[3]. CQI data: WBC, serum glucose and complications;
[4]. Length of hospital stays;
[5]. Surgical outcome by PROMIS scores at 2-weeks postop in surgeon office to be collected by researchers.

Since both QLB/LFCNB nerve block and PAI techniques are both routinely used as standard of care anesthesia for THA, the study intervention will be the randomization to assign patients to one of these treatment options and assess their response from post-op patient questionnaires and data collection.

Eligibility Criteria

Inclusion Criteria:

  • Elective unilateral primary THA
  • All surgical approaches
  • American Society of Anesthesiologist (ASA) status I, II and III.

Exclusion Criteria:

  • Patient refusal;
  • Age less than 18 years
  • Those with cognitive dysfunction, psychiatric disorder, or non-English speaking patients that cannot consent or communicate clear understanding of the protocol with research team;
  • Coagulopathy;


For more information about this study, contact:

Or contact the Help us Discover team on: